ARCT — Arcturus Therapeutics Holdings

Is ARCT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Arcturus Therapeutics Holdings (ARCT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $13.03. The rating moved from Neutral to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Arcturus combines a proprietary mRNA/LNP delivery platform with a set of clinical programs that could generate stepwise value if upcoming readouts and partnerships materialize. Financial health is a focal point given ongoing cash burn typical of platform biotechs; the balance sheet and any near-term financing or partner deals will heavily influence dilution risk. Market conditions are currently risk‑off, which compresses appetite for speculative biotech names and can mute upside absent concrete catalysts. Policy developments around drug pricing and heightened payer scrutiny add uncertainty to prospective commercial outcomes. The company’s strategic collaborations, positive clinical data, or non‑dilutive financing would be the principal upside drivers, while clinical setbacks, funding shortfalls, or adverse pricing/regulatory shifts are the principal downside scenarios.

Key factors

  • Pipeline composition and clinical-readout cadence: near-term value tied to specific program milestones and trial data that will drive shares
  • Cash runway and financing risk: historical cash burn in platform-biotech model implies potential for dilution absent material partnership or non-dilutive funding
  • Platform strength (mRNA/LNP technology): differentiated delivery technology can enable partnerships and long-term licensing value if efficacy/safety hold up
  • Partnerships and collaborator interest: licensing or strategic deals would materially de-risk development and provide funding/validation
  • Macro and sector sentiment: current risk-off market tone reduces appetite for smaller biotech names lacking imminent positive catalysts
  • Regulatory and payer environment: heightened focus on drug pricing and access (Medicare negotiation) could pressure commercial economics for successful assets

Risks

  • Clinical failure or safety signal in a lead program, which would sharply reduce valuation
  • Insufficient cash runway leading to equity raises at dilutive levels or unfavorable financing terms
  • Commercial/pricing pressure from policy actions and payer negotiations reducing future revenue potential
  • Intensifying competition from larger platform players and next‑generation therapies that could limit market share
  • Manufacturing or supply chain disruptions affecting ability to produce clinical or commercial material
  • Low trading liquidity and volatility amplified by sector flows during risk‑off periods

See today's live rating, score and targets

Members see the live hourly rating for ARCT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.